

July 15, 2019

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai: 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai: 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Statement of Investor Complaints.

Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended June 30, 2019:

Sr.No	Particulars	Details
1	No. of Investor Complaints pending at the beginning of the quarter	0
2	No. of Investor Complaints received during the quarter	11
3	No. of Investor Complaints disposed off during the quarter	11
4	No. of Investor Complaints those remaining unresolved at the end of the quarter	0

Please take the same on records.

Yours Faithfully,

For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com